ELOXX PHARMACEUTICALS INC(NASDAQ:ELOX) stock News

ELOX Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Eloxx Pharmaceuticals - Mentions: DE

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

a year ago - By: Eloxx Pharmaceuticals - Mentions: DE

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

a year ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

2 years ago - By: Eloxx Pharmaceuticals - Mentions: DE

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

2 years ago - By: Eloxx Pharmaceuticals

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

2 years ago - By: InvestorPlace - Mentions: ELYS

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

2 years ago - By: Benzinga - Mentions: TCON BLPH OPGN RAIN ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

2 years ago - By: Seeking Alpha

Eloxx Pharmaceuticals prices $2M stock offering (NASDAQ:ELOX)

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

2 years ago - By: Benzinga - Mentions: BEAT BIOL NDRA NVOS ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

2 years ago - By: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

2 years ago - By: InvestorPlace - Mentions: HCTI CVKD ENOB FLJ ...

ELOXX PHARMACEUTICALS INC (ELOX) Stock News

ELOX Latest News, Press Relases and Analysis

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

12 Health Care Stocks Moving In Friday's After-Market Session

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Eloxx Pharmaceuticals prices $2M stock offering (NASDAQ:ELOX)

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

12 Health Care Stocks Moving In Thursday's Intraday Session

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday